Doc code IDS

PTO/SBI08a (08-08)
Approved for use through 09/30/2008, OMB 0851-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE Doc description: Information Disclosure Statement (IDS) Filed Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.

	Application Number		09211297		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Filing Date		1998-12-14		
	First Named Inventor	Boyle	, William J.		
	Art Unit		1644		
	Examiner Name	Szperka, Michael E.			
	Attaces		A 451M IDOWS 101408		

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C	Date	Name of Pate of cited Docu	entee or Applicant iment	Releva	,Columns,L ant Passage s Appear		
	1										
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,L ant Passage s Appear		
	1										
If you wisl	h to a	dd additional U.S. Publ						d buttor	=		
				FOREIG	3N PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colu where Rele Passages o Figures App	vant r Relevant	ть
	1	9626217	wo		A1	1996-08-29	Goto et al. (English Equivalent EP 0 81 A1)				
	2	9700318	wo		A1	1997-01-03	Roodman				
	3	9807840	wo		A1	1998-02-26	Nakagawa et al.				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09211297				
Filing Date		1998-12-14				
First Named Inventor	Boyle	, William J.				
Art Unit		1644				
Examiner Name	Szper	erka, Michael E.				
Attorney Docket Number		A-451M IDS#2-101408				

	4	9846644	WO	A1	1998-10-22	Yamaguchi et al.		
	5	9846751	wo	A1	1998-10-22	Boyle		
	6	9849305	wo	A1	1998-11-05	Boyle et al.		
	7	0874045	EP	A1	1998-10-28	Nakagawa et al.		
	8	0117543	wo	A2	2001-03-15	Dunstan		
	9	0117543	wo	А3	2001-03-15	Dunstan		
	10	0118203	wo	A1	2001-03-15	Dunstan et al.		
	11	0216551	wo	A2	2002-02-28	Choi et al		
	12	0216551	wo	А3	2002-02-28	Choi et al.		
	13	03002713	wo	A2	2003-01-09	Boyle et al₋		
If you wisl	h to a	dd additional Foreign Pa				ease click the Add button		
	NON-PATENT LITERATURE DOCUMENTS Remove							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09211297				
Filing Date		1998-12-14				
First Named Inventor	Boyle	, Wilham J.				
Art Unit		1644				
Examiner Name	Szper	rka, Michael E.				
Attorney Docket Numb	er	A-451M IDS#2-101408				

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	O'Bren, E. A. et al., "Osteoprolegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria", Biochem. Biophys. Res. Commun., 274. 281-290 (2000)	
	2	Oyajbbi et al., "Therapeutic efficacy of a soluble receptor activator of nuclear factor kappa-8-gC Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy", Cancer Res., 61: 2572-2578 (March 15, 2001)	
	3	Peterson et al., "AMG162, A fully human monoclonal antibody against receptor activator of NF-Kappa B ligand (RANKL), rapidly and profoundly suppresses bone rescription in cynomolgus monkey!, Internat! Bone and Mineral Society-Japan Bone and Mineral Society, 2003, Poster Session 2 "Osterodasts", Osaka, Japan (June 6, 2003)	
	4	Reddi, A. H., "Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state", Cell, 89: 151-161 (1997)	
	5	Reiger et al., Clossary of Genetics and Cytogenetics, p. 17, Springer-Verlag Berlin Hediberg, New York (1976)	
	6	Suda, T et al., "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endoor, Rev., 20. 345-357 (1999)	
	7	Takada et al., "A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells", Bone and Mineral, 17, 347-359 (1992)	
	8	Takeyama, S et al., "Low calcium environment effects osteoprolegerin ligandiosteoclast differentiation factor", Blochim. Biophys. Res. Commun., 276: 524-529 (2000)	
	9	Teng, Y. A. et al., "Functional human T-oell immunity and deteoprolegerin ligand control alveolar bone destruction in periodontal infection", J. Clin. Invest., 108; 749-752 (2000)	
	10	Tsuda et al., "Isolation of a novel cutokine from human fibroblasts that specifically inhibits osteoclastogenesis", Biochemical and Biophysical Research Communications, 234(1): 137-142 (1997)	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		09211297				
Filing Date		1998-12-14				
First Named Inventor	Boyle, Wilham J.					
Art Unit		1644				
Examiner Name	Szperka, Michael E.					
Attorney Docket Number		A-451M	IDS#2-101408			

	11		awa, N. et al., "Osteoblasts/stromal cells stimulate osteoclast activentiation factor/RANKI, but no macrophage colony-stimulating factors."			
	12		nabe et al., "Interlukin-4 as a potent inhibitor of bone resorption", i munications, 172(3): 1035-141 (1990)	Biochemical and Bioph	ysical Research	
	13		rd, D. et al., "Expression, purification, and characterization of the t IKL) extracellular domain", Protein Expr. Purif., 20: 48-57 (2000)	numan receptor activati	or of NF-kappaB ligand	
	14		g et al., J. Biol. Chem. "The TRAF Family of Signal Transducers M ptor", 273(43): 28355-28359 (1998)	lediates NF-xB Activati	on by the TRANCE	
	15		da et al , "Suramin suppresses hypercalcemia and osteoclastic bo mous cancer", Cancer Research, 55: 1989-1993 (1995)	ne resorption in nude	mice bearing a human	
	16		g et al., "Turnor necrosis factor-alpha (TNF) stimulates RANKL-inc I receptor and RANK signaling pathways", J. Biol. Chem., 276(1).			
If you wis	sh to a	dd add	ditional non-patent literature document citation information p	lease click the Add	button Add	
			EXAMINER SIGNATURE			
Examine	r Signa	ature		Date Considered		
*EXAMIN	IER: Ir	nitial if	reference considered, whether or not citation is in conforma	ance with MPEP 609	. Draw line through a	

1.5ee KinG Codes of USPTO Patient Documents at year LISETQ GOU, or MPEP 901.64. ² Exits of fillow that issued the document, by the how-lefter code (WIPO Standard ST3, ³ Ser Juapanes patient concurrent, by manifold on the year of the Proprior many precedure he resident number of the patient document. ⁴ Kind of documents by the appropriate symbols as indicated on the document wile O Standard ST, 16 if possible. ³ Applicant is to place a check mark here if English language in translation in attacked.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.